Amplia Therapeutics: Half Yearly Report and Accounts
Filed with ASX · · 27 pages · English
This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics. Investor Contact: Dr Chris Burns Chief Executive Officer [email protected] Investor Contact (US): Media Contact: Robert Giordano GGroup Life Sciences [email protected] Haley Chartres [email protected] +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Positive Response from US FDA to Amplia's Type D Meeting
- Amplia Receives R&D Tax Rebate Totalling $3.77 Million
- First patient dosed in new pancreatic cancer trial
- Amplia Share Purchase Plan Raises $2.65 Million
- Positive ACCENT Trial Topline Data Released
Later from Amplia Therapeutics
- Key Narmafotinib Patent Granted in the U.S.
- Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th
- Additional Confirmed Response Reported as Part of Amplia Investor Presentation
- Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
- Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics